Pharmaceuticals

CureVac is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Vaccine & Immunotherapy Developers 1 ranking category Overview

CSL is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Global Pharmaceutical Companies 1 ranking category Overview

CSL Seqirus is one of the world’s most important influenza vaccine developers and manufacturers. As part of CSL, the business benefits from biologics manufacturing expertise, global public health relationships, and strong experience in seasonal and pandemic influenza vaccine supply.

CSL Behring is one of the world’s leading specialty biologics companies, focused on plasma-derived therapies, immunoglobulins, hemophilia, hereditary angioedema, immunology, and rare diseases. Its business model is highly specialized, combining biologic manufacturing, plasma collection, global distribution, and specialist medicine.

CRISPR Therapeutics is one of the most important gene editing companies globally. Its partnership with Vertex on Casgevy established CRISPR editing as an approved therapeutic modality and marked one of the most important milestones in the history of genetic medicine.

CordenPharma is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Biomanufacturing & CDMO Providers 1 ranking category Overview

Corcept Therapeutics is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Specialty Pharma Companies 1 ranking category Overview

Collegium Pharmaceutical is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Specialty Pharma Companies 1 ranking category Overview

ClinChoice is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Contract Research Organizations 1 ranking category Overview

Clario is a clinical trial technology and endpoint services company supporting pharmaceutical and biotechnology sponsors through electronic clinical outcome assessments, cardiac safety, medical imaging, respiratory endpoints, and trial data solutions.

Chugai Pharmaceutical is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Global Pharmaceutical Companies 1 ranking category Overview

Chiesi Global Rare Diseases is a focused rare disease platform within Chiesi Group. It develops and commercializes therapies for rare metabolic, lysosomal storage, and specialty conditions, with a growing international presence in orphan disease markets.

Chiesi Farmaceutici is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Specialty Pharma Companies 1 ranking category Overview

Cellectis is one of the earlier pioneers in gene-edited allogeneic cell therapy. The company focuses on using gene editing to create off-the-shelf CAR-T cell therapies, primarily for oncology.

Catalyst Pharmaceuticals is a specialist rare disease company focused on neuromuscular and neurological disorders. Its commercial platform is closely linked to Lambert-Eaton myasthenic syndrome and related rare neuromuscular indications.

Catalent is one of the most important global CDMO providers, with broad capabilities across biologics, sterile fill-finish, oral solid dose, softgel technologies, clinical supply services, packaging, and advanced delivery formats. The company’s platform serves pharmaceutical, biotechnology, and consumer health clients across development and commercial supply.

Caribou Biosciences is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Cell & Gene Therapy Developers 1 ranking category Overview

CanSino Biologics is an institution recognized in the 2026 Ranking News professional-ranking universe. Highest 2026 tier: Tier III Vaccine & Immunotherapy Developers 1 ranking category Overview

Cambrex is a specialist CDMO focused on small molecule drug substance and related development services. Its capabilities include API development, process chemistry, analytical development, controlled substances, early-stage development, and commercial manufacturing.

Cabaletta Bio is a specialist developer of engineered cell therapies for autoimmune diseases. The company is part of a broader movement to apply CAR-T and related cell therapy technologies beyond cancer, especially in diseases where pathogenic immune cells may be reset or depleted.